First National's 15min chart shows KDJ Death Cross, Bearish Marubozu pattern.

The 15-minute chart of First National's stock price triggered a KDJ Death Cross and a bearish Marubozu at 10:15 AM EST on October 16, 2025. This indicates that the momentum of the stock price is shifting towards the downside and has the potential to further decrease, with sellers dominating the market. The bearish momentum is likely to continue.

Pulmatrix Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company, recently reported its third quarter 2025 financial results and announced a significant divestment plan for its migraine and inhalation assets. The company also provided an update on its merger with Cullgen, which is expected to close in the near future.

# Financial Performance

The company reported zero revenue in Q3 2025, a significant decrease from $1.6 million in Q2 2025. Research and development (R&D) expenses were reduced to under $0.1 million from $2.8 million year-over-year. The cash position as of September 30, 2025, stood at $5.8 million, providing sufficient funding for operations through the merger closing.

# Divestment Plan

Pulmatrix has announced a divestment plan for its migraine and inhalation assets, including the proprietary iSPERSE™ technology and three clinical programs. This move is part of the company's strategic merger with Cullgen, which aims to create a Nasdaq-listed company focused on targeted protein degradation therapies. The merger, approved by stockholders on June 16, 2025, awaits approval from Nasdaq and the China Security Regulatory Commission.

# Merger Details

The merger with Cullgen is expected to close in the near future, creating a combined entity with approximately $65 million in cash. Post-merger, the new company will focus on targeted protein degrader therapies with three Phase 1 clinical programs. Pulmatrix's cash position of $5.8 million as of June 30, 2025, is expected to fund operations through the merger closing.

# Market Implications

The financial results and the divestment plan indicate a strategic shift for Pulmatrix, focusing on targeted protein degradation therapies. The bearish market signals, including the KDJ Death Cross and bearish Marubozu, suggest that the momentum of the stock price is shifting towards the downside, with sellers dominating the market. Investors should closely monitor the merger progress and the company's financial performance in the coming quarters.

References

- Pulmatrix Stock Price, News & Analysis: `https://www.stocktitan.net/news/PULM/`